Advocacy at a Glance STEVEN GROSSMAN 10/28/16 Advocacy at a Glance STEVEN GROSSMAN 10/28/16 Down-Ballot Congressional Races: Another Post-Election Unknown Read More Analysis and Commentary STEVEN GROSSMAN 10/21/16 Analysis and Commentary STEVEN GROSSMAN 10/21/16 Plus ça Change, Plus c'est la Même Chose (or Maybe Not) Read More Advocacy at a Glance STEVEN GROSSMAN 10/21/16 Advocacy at a Glance STEVEN GROSSMAN 10/21/16 Presidential Transition Planning Underway Read More Analysis and Commentary STEVEN GROSSMAN 10/14/16 Analysis and Commentary STEVEN GROSSMAN 10/14/16 And Now Much Depends on Election Day Outcomes Read More Advocacy at a Glance STEVEN GROSSMAN 10/14/16 Advocacy at a Glance STEVEN GROSSMAN 10/14/16 Congress to Return November 14; Government Funding Top Priority Read More Advocacy at a Glance STEVEN GROSSMAN 10/1/16 Advocacy at a Glance STEVEN GROSSMAN 10/1/16 A CR Gets Passed ... But Has Fiscal Implications Read More Advocacy at a Glance STEVEN GROSSMAN 10/1/16 Advocacy at a Glance STEVEN GROSSMAN 10/1/16 CR through December 9 Passes; Congress in Recess Read More Analysis and Commentary STEVEN GROSSMAN 9/23/16 Analysis and Commentary STEVEN GROSSMAN 9/23/16 FDA Purchasing Power is on the Line Read More Advocacy at a Glance STEVEN GROSSMAN 9/23/16 Advocacy at a Glance STEVEN GROSSMAN 9/23/16 Continuing Resolution Still in Negotiations; One Week to Go or Else Read More Analysis and Commentary STEVEN GROSSMAN 9/16/16 Analysis and Commentary STEVEN GROSSMAN 9/16/16 What to Expect When You are Expecting a Lame Duck Read More Advocacy at a Glance STEVEN GROSSMAN 9/16/16 Advocacy at a Glance STEVEN GROSSMAN 9/16/16 Alliance District Lobby Days Planned for Mid-October. Please Participate Read More Analysis and Commentary STEVEN GROSSMAN 9/9/16 Analysis and Commentary STEVEN GROSSMAN 9/9/16 Omnibus, Minibus, or Any Type of Bus at All? Read More Advocacy at a Glance STEVEN GROSSMAN 9/9/16 Advocacy at a Glance STEVEN GROSSMAN 9/9/16 CDRH Director Shuren’s Presentation Well Received. Read More Analysis and Commentary STEVEN GROSSMAN 8/28/16 Analysis and Commentary STEVEN GROSSMAN 8/28/16 The Cost -- and the Importance -- of Public Attention Read More Advocacy at a Glance STEVEN GROSSMAN 8/28/16 Advocacy at a Glance STEVEN GROSSMAN 8/28/16 Congress Returns Soon; Unclear How Long It Will Stay Read More Analysis and Commentary STEVEN GROSSMAN 8/20/16 Analysis and Commentary STEVEN GROSSMAN 8/20/16 Exceptionalism in Predictably Challenging Times Read More Advocacy at a Glance STEVEN GROSSMAN 8/20/16 Advocacy at a Glance STEVEN GROSSMAN 8/20/16 Appropriations Status Unchanged Read More Analysis and Commentary STEVEN GROSSMAN 8/15/16 Analysis and Commentary STEVEN GROSSMAN 8/15/16 Management of Accountability to Varied Audiences Read More Advocacy at a Glance STEVEN GROSSMAN 8/15/16 Advocacy at a Glance STEVEN GROSSMAN 8/15/16 Key Congressional Decisions: CR or Omnibus; December or March Read More Analysis and Commentary STEVEN GROSSMAN 7/29/16 Analysis and Commentary STEVEN GROSSMAN 7/29/16 FDA Must Do More ... But How Much More for Less? Read More Newer Posts Older Posts
Advocacy at a Glance STEVEN GROSSMAN 10/28/16 Advocacy at a Glance STEVEN GROSSMAN 10/28/16 Down-Ballot Congressional Races: Another Post-Election Unknown Read More
Analysis and Commentary STEVEN GROSSMAN 10/21/16 Analysis and Commentary STEVEN GROSSMAN 10/21/16 Plus ça Change, Plus c'est la Même Chose (or Maybe Not) Read More
Advocacy at a Glance STEVEN GROSSMAN 10/21/16 Advocacy at a Glance STEVEN GROSSMAN 10/21/16 Presidential Transition Planning Underway Read More
Analysis and Commentary STEVEN GROSSMAN 10/14/16 Analysis and Commentary STEVEN GROSSMAN 10/14/16 And Now Much Depends on Election Day Outcomes Read More
Advocacy at a Glance STEVEN GROSSMAN 10/14/16 Advocacy at a Glance STEVEN GROSSMAN 10/14/16 Congress to Return November 14; Government Funding Top Priority Read More
Advocacy at a Glance STEVEN GROSSMAN 10/1/16 Advocacy at a Glance STEVEN GROSSMAN 10/1/16 A CR Gets Passed ... But Has Fiscal Implications Read More
Advocacy at a Glance STEVEN GROSSMAN 10/1/16 Advocacy at a Glance STEVEN GROSSMAN 10/1/16 CR through December 9 Passes; Congress in Recess Read More
Analysis and Commentary STEVEN GROSSMAN 9/23/16 Analysis and Commentary STEVEN GROSSMAN 9/23/16 FDA Purchasing Power is on the Line Read More
Advocacy at a Glance STEVEN GROSSMAN 9/23/16 Advocacy at a Glance STEVEN GROSSMAN 9/23/16 Continuing Resolution Still in Negotiations; One Week to Go or Else Read More
Analysis and Commentary STEVEN GROSSMAN 9/16/16 Analysis and Commentary STEVEN GROSSMAN 9/16/16 What to Expect When You are Expecting a Lame Duck Read More
Advocacy at a Glance STEVEN GROSSMAN 9/16/16 Advocacy at a Glance STEVEN GROSSMAN 9/16/16 Alliance District Lobby Days Planned for Mid-October. Please Participate Read More
Analysis and Commentary STEVEN GROSSMAN 9/9/16 Analysis and Commentary STEVEN GROSSMAN 9/9/16 Omnibus, Minibus, or Any Type of Bus at All? Read More
Advocacy at a Glance STEVEN GROSSMAN 9/9/16 Advocacy at a Glance STEVEN GROSSMAN 9/9/16 CDRH Director Shuren’s Presentation Well Received. Read More
Analysis and Commentary STEVEN GROSSMAN 8/28/16 Analysis and Commentary STEVEN GROSSMAN 8/28/16 The Cost -- and the Importance -- of Public Attention Read More
Advocacy at a Glance STEVEN GROSSMAN 8/28/16 Advocacy at a Glance STEVEN GROSSMAN 8/28/16 Congress Returns Soon; Unclear How Long It Will Stay Read More
Analysis and Commentary STEVEN GROSSMAN 8/20/16 Analysis and Commentary STEVEN GROSSMAN 8/20/16 Exceptionalism in Predictably Challenging Times Read More
Advocacy at a Glance STEVEN GROSSMAN 8/20/16 Advocacy at a Glance STEVEN GROSSMAN 8/20/16 Appropriations Status Unchanged Read More
Analysis and Commentary STEVEN GROSSMAN 8/15/16 Analysis and Commentary STEVEN GROSSMAN 8/15/16 Management of Accountability to Varied Audiences Read More
Advocacy at a Glance STEVEN GROSSMAN 8/15/16 Advocacy at a Glance STEVEN GROSSMAN 8/15/16 Key Congressional Decisions: CR or Omnibus; December or March Read More
Analysis and Commentary STEVEN GROSSMAN 7/29/16 Analysis and Commentary STEVEN GROSSMAN 7/29/16 FDA Must Do More ... But How Much More for Less? Read More
